|Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children|
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
|NTRK fusion-positive cancers and TRK inhibitor therapy|
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
|Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials|
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
|Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry|
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
|Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 …|
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
|Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 SkippingMET Inhibitors in MET Exon 14 Splice Variant Lung Cancer|
PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ...
Cancer discovery 5 (8), 842-849, 2015
|HER kinase inhibition in patients with HER2-and HER3-mutant cancers|
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
|Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas|
A Drilon, L Wang, A Hasanovic, Y Suehara, D Lipson, P Stephens, J Ross, ...
Cancer discovery 3 (6), 630-635, 2013
|Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials|
DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ...
The Lancet Oncology 21 (4), 531-540, 2020
|Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesMolecular Profiling to Guide …|
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
|Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer|
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
|Efficacy of Selpercatinib in RET-Altered Thyroid Cancers|
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
|Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial|
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ...
The Lancet Oncology 17 (12), 1653-1660, 2016
|Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsLarge Cell Neuroendocrine …|
N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ...
Clinical Cancer Research 22 (14), 3618-3629, 2016
|Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions|
JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ...
The American journal of surgical pathology 41 (11), 1547, 2017
|Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
JAMA oncology 5 (10), 1411-1420, 2019
|Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial|
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532, 2018
|NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls|
JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ...
Modern Pathology 33 (1), 38-46, 2020
|A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsNext-Generation TRK …|
A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ...
Cancer discovery 7 (9), 963-972, 2017
|Targeting MET in lung cancer: will expectations finally be MET?|
A Drilon, F Cappuzzo, SHI Ou, DR Camidge
Journal of Thoracic Oncology 12 (1), 15-26, 2017